A Phase 2 interventional study of ALD403 and Placebo in Migraine Disorders, sponsored by Alder Biopharmaceuticals, Inc.. Completed at 92 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-04-08.
Sponsored by Alder Biopharmaceuticals, Inc. (part of H. Lundbeck A/S) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 5th largest by enrollment, is the only one that started in 2014, is the only one in phase 2, and was the 3rd registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 665 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
This study is registered under Alder Biopharmaceuticals, Inc., one of the names counted as H. Lundbeck A/S. Under that name alone:
Alder Biopharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 6th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 2, and was the 3rd registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALD403 Dose Level 1 (IV)
Biological: ALD403
ALD403 Dose Level 2 (IV)
Biological: ALD403
ALD403 Dose Level 3 (IV)
Biological: ALD403
ALD403 Dose Level 4 (IV)
Biological: ALD403
Placebo (IV)
Biological: Placebo
Also known as: Eptinezumab-jjmr, Vyepti
75% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.
Time frame: 12 Weeks
50% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline
Time frame: Weeks 1-12
50% Headache Responder Rate
Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline
Time frame: Weeks 1-12
100% Headache Responder Rate
Participants with an average reduction in headache days of at least 100% over Weeks 1 to 12, as compared with baseline
Time frame: Weeks 1-12
100% Migraine Responder Rate
Participants with an average reduction in migraine days of at least 100% over Weeks 1 to 12, as compared with baseline
Time frame: Weeks 1-12
The Change From Baseline in Monthly Headache Days, Weeks 1-12
Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Time frame: Weeks 1-12
The Change From Baseline in Monthly Migraine Days, Weeks 1-12
Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Time frame: Weeks 1-12
Change From Baseline in Percentage of Severe Migraines
The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12
Time frame: Weeks 1-12
Change From Baseline in Percentage of Severe Headaches
The change from baseline in percentage of headaches that are classified as severe over Weeks 9-12
Time frame: Weeks 9-12
The Change From Baseline to Week 12 in HIT-6 Total Score
The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). A score of 60 or above is labeled as "severe".
Time frame: Baseline to 12
Percent Change From Baseline in Headache Days
Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Time frame: Weeks 1-12
Percent Change From Baseline in Migraine Days
Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
Time frame: Weeks 1-12
Time to First Migraine After Dosing
The median number of days after dosing a participant had the next migraine using the eDiary as the recall method
Time frame: Baseline to Week 49 (End of Study)
Change From Baseline in Monthly Migraine Attacks, Weeks 1-12
The number of monthly migraine attacks summarized over Weeks 1-12. A migraine attack is defined as 1 continuously recorded migraine. One attack may result in multiple migraine days
Time frame: Weeks 1-12
Change From Baseline in Monthly Headache Episodes, Weeks 1-12
The number of monthly headache episodes as summarized over Weeks 1-12. A headache episode is defined as 1 continuously recorded headache. One episode may result in multiple headache days
Time frame: Weeks 1-12
Change From Baseline in Monthly Migraine Hours, Weeks 1-12
Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.
Time frame: Weeks 1-12
Change From Baseline in Monthly Headache Hours, Weeks 1-12
Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.
Time frame: Weeks 1-12
Change From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication
The percent of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.
Time frame: Weeks 9-12
Change From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication
The percent of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.
Time frame: Weeks 9-12
Baseline and Change From Baseline in Short Form Health Survey (SF-36, Version 2.0) at Week 12
The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (range: 0=worst to 100=best). Increases from baseline indicate improvement.
Time frame: Baseline to Week 12
| Milestone | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Started | 131 | 133 | 134 | 133 | 134 |
| Randomized and treated | 120 | 123 | 122 | 130 | 121 |
| Completed | 97 | 96 | 92 | 100 | 98 |
| Not completed | 34 | 37 | 42 | 33 | 36 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 6 | 7 | 5 | 2 | 10 |
| Withdrew: Lost to follow-up | 11 | 16 | 15 | 16 | 8 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 4 | 7 | 3 | 3 |
| Withdrew: Terminated by sponsor | 4 | 4 | 4 | 6 | 4 |
| Withdrew: Worsening of study indication | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Study burden | 5 | 4 | 7 | 5 | 7 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 2 |
Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| 75% Migraine Responder Rate | 38 | 37 | 33 | 33 | 24 |
Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| 50% Migraine Responder Rate | 65 | 65 | 65 | 54 | 47 |
Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| 50% Headache Responder Rate | 59 | 55 | 55 | 48 | 39 |
Participants with an average reduction in headache days of at least 100% over Weeks 1 to 12, as compared with baseline
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| 100% Headache Responder Rate | 4 | 0 | 0 | 1 | 1 |
Participants with an average reduction in migraine days of at least 100% over Weeks 1 to 12, as compared with baseline
| Participants | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| 100% Migraine Responder Rate | 9 | 6 | 5 | 10 | 3 |
Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
| days | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Monthly Headache Days, Weeks 1-12 | -9.6 ± 6.94 | -8.9 ± 6.79 | -9.2 ± 6.33 | -7.5 ± 6.93 | -6.9 ± 6.37 |
Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
| days | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline in Monthly Migraine Days, Weeks 1-12 | -8.2 ± 7.00 | -7.7 ± 6.87 | -7.9 ± 6.38 | -6.7 ± 6.80 | -5.6 ± 6.56 |
The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12
| percentage of severe migraines | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Percentage of Severe Migraines | -20.7 ± 29.47 | -15.9 ± 27.38 | -17.2 ± 26.98 | -16.1 ± 29.80 | -9.7 ± 27.32 |
The change from baseline in percentage of headaches that are classified as severe over Weeks 9-12
| percentage of severe headaches | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Percentage of Severe Headaches | -19.91 ± 25.800 | -10.36 ± 28.004 | -12.17 ± 30.197 | -11.42 ± 30.517 | -6.48 ± 27.211 |
The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact). A score of 60 or above is labeled as "severe".
| percentage of HIT-6 total score | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| The Change From Baseline to Week 12 in HIT-6 Total Score | -60.4 | -43.4 | -34.9 | -34.8 | -28.4 |
Monthly headache days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
| percentage of headache days | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Headache Days | -46.12 ± 31.481 | -43.09 ± 33.912 | -44.37 ± 28.620 | -37.20 ± 34.112 | -34.02 ± 30.970 |
Monthly migraine days, as measured by eDiary. 4-weekly intervals averaged across weeks 1-12.
| percentage of migraine days | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Migraine Days | -48.88 ± 41.243 | -46.79 ± 40.983 | -46.74 ± 36.588 | -40.80 ± 40.133 | -35.37 ± 41.100 |
The median number of days after dosing a participant had the next migraine using the eDiary as the recall method
| Days | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Time to First Migraine After Dosing | 4.0 (3.0 to 5.0) | 4.0 (3.0 to 5.0) | 3.0 (2.0 to 5.0) | 4.0 (3.0 to 5.0) | 2.0 (1.0 to 3.0) |
The number of monthly migraine attacks summarized over Weeks 1-12. A migraine attack is defined as 1 continuously recorded migraine. One attack may result in multiple migraine days
| Migraine Attacks | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Monthly Migraine Attacks, Weeks 1-12 | -6.8 ± 5.4 | -6.5 ± 4.9 | -6.9 ± 5.0 | -6.2 ± 5.2 | -5.5 ± 5.0 |
The number of monthly headache episodes as summarized over Weeks 1-12. A headache episode is defined as 1 continuously recorded headache. One episode may result in multiple headache days
| Headache Episodes | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Monthly Headache Episodes, Weeks 1-12 | -8.2 ± 5.54 | -8.0 ± 5.37 | -8.3 ± 5.55 | -7.3 ± 5.37 | -7.0 ± 5.13 |
Migraine hours are the sum of the duration of migraines within 4 week intervals, and the average 4 week duration within 12 week intervals.
| Migraine Hours | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Monthly Migraine Hours, Weeks 1-12 | -70.9 ± 100.34 | -64.2 ± 114.58 | -63.1 ± 84.56 | -49.2 ± 103.83 | -34.9 ± 100.87 |
Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.
| Headache Hours | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Monthly Headache Hours, Weeks 1-12 | -73.9 ± 101.53 | -60.9 ± 114.77 | -62.9 ± 81.89 | -47.5 ± 102.84 | -38.7 ± 99.26 |
The percent of migraines with acute medication usage. Participants with no migraines will be included with a rate of zero.
| percentage of acute medication migraines | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to Weeks 9-12 in Percentage of Migraines With Use of Acute Medication | -15.43 ± 39.121 | -10.36 ± 43.890 | -4.44 ± 37.746 | -10.03 ± 40.460 | -9.60 ± 37.451 |
The percent of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.
| percentage of acute medication headaches | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to Weeks 9-12 in Percentage of Headaches With Use of Acute Medication | -5.98 ± 34.144 | -3.27 ± 34.419 | 1.52 ± 30.013 | -3.14 ± 32.853 | -3.42 ± 32.890 |
The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks (range: 0=worst to 100=best). Increases from baseline indicate improvement.
| SF-36 Score | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Physical Functioning - Baseline | 50.5 ± 8.7 | 50.6 ± 7.8 | 51.1 ± 7.6 | 50.3 ± 8.4 | 50.2 ± 6.5 |
| Physical Functioning - Week 12 | 53.6 ± 5.0 | 51.2 ± 8.3 | 52.5 ± 7.2 | 51.3 ± 7.9 | 51.9 ± 6.1 |
| Role Physical - Baseline | 43.9 ± 9.5 | 45.2 ± 9.3 | 45.6 ± 9.3 | 44.9 ± 9.9 | 44.3 ± 9.6 |
| Role Physical - Week 12 | 50.9 ± 7.2 | 48.9 ± 9.3 | 49.9 ± 7.7 | 47.9 ± 9.9 | 48.5 ± 8.3 |
| Bodily Pain -Baseline | 42.7 ± 9.5 | 42.7 ± 9.6 | 44.5 ± 9.9 | 43.0 ± 9.6 | 42.5 ± 9.4 |
| Bodily Pain - Week 12 | 48.9 ± 8.4 | 46.5 ± 9.9 | 48.1 ± 9.2 | 46.6 ± 9.3 | 46.0 ± 9.5 |
| General Health - Baseline | 50.4 ± 9.2 | 50.7 ± 9.8 | 50.9 ± 8.7 | 51.1 ± 9.5 | 50.7 ± 9.8 |
| General Health - Week 12 | 51.8 ± 8.7 | 50.7 ± 10.2 | 50.7 ± 9.2 | 52.7 ± 9.8 | 50.6 ± 10.0 |
| Vitality - Baseline | 48.3 ± 8.9 | 50.1 ± 10.6 | 49.6 ± 9.8 | 49.4 ± 10.1 | 48.1 ± 10.9 |
| Vitality - Week 12 | 51.3 ± 7.8 | 50.9 ± 10.5 | 50.6 ± 11.3 | 50.7 ± 10.6 | 51.1 ± 10.2 |
| Social Functioning - Baseline | 45.0 ± 10.8 | 46.3 ± 10.1 | 46.8 ± 10.7 | 45.5 ± 10.4 | 45.4 ± 10.3 |
| Social Functioning - Week 12 | 50.5 ± 8.1 | 48.7 ± 10.1 | 49.5 ± 9.0 | 47.7 ± 9.8 | 48.1 ± 8.7 |
| Role Emotional - Baseline | 50.2 ± 9.1 | 49.4 ± 9.6 | 49.4 ± 9.7 | 49.8 ± 10.3 | 50.9 ± 8.1 |
| Role Emotional - Week 12 | 51.4 ± 8.2 | 50.2 ± 9.0 | 51.2 ± 7.2 | 50.9 ± 8.4 | 51.0 ± 8.3 |
| Mental Health - Baseline | 51.4 ± 8.4 | 52.0 ± 9.3 | 51.8 ± 9.5 | 51.4 ± 9.5 | 50.8 ± 9.8 |
| Mental Health - Week 12 | 52.1 ± 8.8 | 50.8 ± 10.1 | 51.2 ± 9.5 | 52.2 ± 9.5 | 52.4 ± 8.8 |
| Mental Component Score - Baseline | 50.4 ± 9.4 | 50.9 ± 9.7 | 50.5 ± 9.6 | 50.4 ± 9.9 | 50.5 ± 9.0 |
| Mental Component Score - Week 12 | 51.2 ± 9.0 | 50.5 ± 9.7 | 50.7 ± 9.4 | 51.3 ± 9.3 | 51.5 ± 8.9 |
| Physical Component Score - Baseline | 45.5 ± 8.4 | 46.1 ± 8.4 | 47.1 ± 7.7 | 46.1 ± 8.3 | 45.5 ± 7.9 |
| Physical Component Score - Week 12 | 51.2 ± 6.8 | 49.0 ± 8.6 | 50.1 ± 7.0 | 48.8 ± 8.5 | 48.4 ± 8.1 |
Collected over Baseline to Week 49 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 300 mg ALD403 | 0/121 (0%) | 7/121 (5.8%) | 40/121 (33.1%) |
| 100 mg ALD403 | 0/122 (0%) | 4/122 (3.3%) | 38/122 (31.1%) |
| 30 mg ALD403 | 0/122 (0%) | 0/122 (0%) | 26/122 (21.3%) |
| 10 mg ALD403 | 0/130 (0%) | 1/130 (0.8%) | 35/130 (26.9%) |
| Placebo | 0/121 (0%) | 1/121 (0.8%) | 37/122 (30.3%) |
| Event | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Gastroenteritis viralInfections and infestations | 1/121 | 0/122 | 0/122 | 0/130 | 0/121 |
| Vaginal abscessInfections and infestations | 1/121 | 0/122 | 0/122 | 0/130 | 0/121 |
| ConcussionInjury, poisoning and procedural complications | 1/121 | 0/122 | 0/122 | 0/130 | 0/121 |
| Head injuryInjury, poisoning and procedural complications | 1/121 | 0/122 | 0/122 | 0/130 | 0/121 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/121 | 1/122 | 0/122 | 0/130 | 0/121 |
| ConvulsionNervous system disorders | 1/121 | 0/122 | 0/122 | 0/130 | 0/121 |
| Serotonin syndromeNervous system disorders | 1/121 | 0/122 | 0/122 | 0/130 | 0/121 |
| Suicidal ideationPsychiatric disorders | 0/121 | 0/122 | 0/122 | 1/130 | 1/121 |
| Pelvic painRenal and urinary disorders | 1/121 | 0/122 | 0/122 | 0/130 | 0/121 |
| Respiratory distressReproductive system and breast disorders | 1/121 | 0/122 | 0/122 | 0/130 | 0/121 |
| Event | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 13/121 | 8/122 | 7/122 | 9/130 | 6/122 |
| DizzinessNervous system disorders | 2/121 | 12/122 | 3/122 | 11/130 | 9/122 |
| NasopharyngitisInfections and infestations | 9/121 | 8/122 | 3/122 | 6/130 | 6/122 |
| NauseaGastrointestinal disorders | 8/121 | 9/122 | 4/122 | 6/130 | 9/122 |
| BronchitisInfections and infestations | 4/121 | 4/122 | 4/122 | 4/130 | 9/122 |
| SinusitisInfections and infestations | 8/121 | 3/122 | 6/122 | 8/130 | 6/122 |
| MigraineNervous system disorders | 1/121 | 7/122 | 3/122 | 2/130 | 2/122 |
| Urinary tract infectionInfections and infestations | 6/121 | 3/122 | 1/122 | 4/130 | 5/122 |
Safety population includes all subjects who received investigational product or placebo. 3 participants received duplicate randomization, participants are summarized within treatment group for which they actually received treatment.
| Age, Continuous(years) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 37.2 ± 10.0 | 36.7 ± 9.4 | 35.7 ± 9.4 | 36.4 ± 10.3 | 37.2 ± 9.2 | 36.6 ± 19.7 |
| Sex: Female, Male(Participants) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 98 | 104 | 111 | 113 | 109 | 535 |
| Male | 23 | 18 | 11 | 17 | 12 | 81 |
| Ethnicity (NIH/OMB)(Participants) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 18 | 23 | 17 | 27 | 16 | 101 |
| Not Hispanic or Latino | 103 | 99 | 105 | 103 | 105 | 515 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 2 | 1 | 4 |
| Asian | 1 | 0 | 0 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 4 | 12 | 14 | 12 | 7 | 49 |
| White | 114 | 108 | 103 | 113 | 109 | 547 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 3 | 2 | 3 | 12 |
| Region of Enrollment(participants) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|---|
| New Zealand | 7 | 1 | 0 | 1 | 2 | 11 |
| United States | 101 | 106 | 107 | 115 | 99 | 528 |
| Georgia | 11 | 9 | 14 | 9 | 15 | 58 |
| Australia | 2 | 6 | 1 | 5 | 5 | 19 |
| Baseline Migraine Days(Participants) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|---|
| < 20 days | 84 | 85 | 87 | 90 | 84 | 430 |
| ≥ 20 days | 37 | 37 | 35 | 40 | 37 | 186 |
| Medication Overuse Status(Participants) | 300 mg ALD403 | 100 mg ALD403 | 30 mg ALD403 | 10 mg ALD403 | Placebo | Total |
|---|---|---|---|---|---|---|
| No | 56 | 62 | 57 | 64 | 57 | 296 |
| Yes | 65 | 60 | 65 | 66 | 64 | 320 |
The record gives a start of Oct 2014, a primary completion of Mar 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2020, 4 years after primary completion. A results delay was requested in Sep 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab
Alder Biopharmaceuticals, Inc. →